Research progress of biochemical diagnostic markers of subjective cognitive decline

Yixin Chen; Lizhen Cheng; Ya Miao

doi:10.13406/j.cnki.cyxb.002924

您当前的位置：

首页 >

文章列表页 >

Research progress of biochemical diagnostic markers of subjective cognitive decline

Correlation analysis of cognitive impairment and peripheral biomarkers | 更新时间：2022-06-24

- Research progress of biochemical diagnostic markers of subjective cognitive decline
- Journal of Shanxi Agricultural Sciences Vol. 46, Issue 11, Pages: 1348-1351(2021)
- 作者机构：
  
  上海交通大学附属第六人民医院老年病科，上海　200233
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.002924
  CLC： R749.16
- Published：28 November 2021，
  
  Received：06 July 2021，
扫描看全文
Yixin Chen, Lizhen Cheng, Ya Miao. Research progress of biochemical diagnostic markers of subjective cognitive decline. [J]. Journal of Shanxi Agricultural Sciences 46(11):1348-1351(2021)
DOI：

Yixin Chen, Lizhen Cheng, Ya Miao. Research progress of biochemical diagnostic markers of subjective cognitive decline. [J]. Journal of Shanxi Agricultural Sciences 46(11):1348-1351(2021) DOI： 10.13406/j.cnki.cyxb.002924.

摘要

阿尔茨海默病（Alzheimer's disease，AD）是痴呆的主要病因之一，主观认知下降（subjective cognitive decline，SCD）被认为是AD的临床前期，早期诊断SCD对AD的防治具有重大意义。在SCD的各种诊断方法中，生化诊断手段是一种较为简单、成本低廉、创伤小的诊断方式。将生化诊断方法与神经心理评估方式相结合，在SCD的诊断中具有较好的前景。本文就SCD的脑脊液、血浆、尿液等生化检测方法的研究进行综述。

Abstract

Alzheimer's disease (AD) is one of the main causes of dementia

and subjective cognitive decline (SCD) is considered as the pre-clinical stage of AD. Early diagnosis of SCD is of great significance to the prevention and treatment of AD. Among various diagnostic methods of SCD

biochemical diagnosis is one relatively simple

low cost and less invasive. The combination of biochemical diagnosis and neuropsychological assessment has a good prospect in the diagnosis of SCD. Therefore

this paper has reviewed the research on cerebrospinal fluid

plasma

urine and other biochemical detection methods of SCD.

关键词

主观认知下降阿尔茨海默病生化诊断标志物

Keywords

subjective cognitive declineAlzheimer's diseasebiochemical diagnostic markers

references

Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer's disease[J]. Lancet, 2016, 388(10043):505-517.

Petersen RC. How early can we diagnose Alzheimer disease(and is it sufficient)?The 2017 wartenberg lecture[J]. Neurology, 2018, 91(9):395-402.

van Harten AC, Mielke MM, Swenson-Dravis DM, et al. Subjective cognitive decline and risk of MCI: the Mayo clinic study of aging[J]. Neurology, 2018, 91(4):e300-e312.

Reisberg B, Ferris SH, de Leon MJ, et al. The global deterioration scale for assessment of primary degenerative dementia[J]. Am J Psychiatry, 1982, 139(9):1136-1139.

Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease[J]. Alzheimers Dement, 2014, 10(6):844-852.

Mitchell AJ, Beaumont H, Ferguson D, et al. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: Meta-analysis[J]. Acta Psychiatr Scand, 2014, 130(6):439-451.

Verlinden VJA, van der Geest JN, de Bruijn RFAG, et al. Trajectories of decline in cognition and daily functioning in preclinical dementia[J]. Alzheimers Dement, 2016, 12(2):144-153.

Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer's disease[J]. Annu Rev Clin Psychol, 2017, 13:369-396.

Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and Metaanalysis[J]. Lancet Neurol, 2016, 15(7):673-684.

Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline[J]. Neurology, 2020, 95(9):e1134-e1143.

Wolfsgruber S, Jessen F, Koppara A, et al. Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI[J]. Neurology, 2015, 84(12):1261-1268.

Miebach L, Wolfsgruber S, Polcher A, et al. Which features of subjective cognitive decline are related to amyloid pathology?Findings from the DELCODE study[J]. Alzheimers Res Ther, 2019, 11(1):66.

Cicognola C, Satir TM, Brinkmalm G, et al. Tauopathy-associated tau fragment ending at amino acid 224 is generated by calpain-2 cleavage[J]. J Alzheimers Dis, 2020, 74(4):1143-1156.

Cicognola C, Brinkmalm G, Wahlgren J, et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease[J]. Acta Neuropathol, 2019, 137(2):279-296.

Cicognola C, Hansson O, Scheltens P, et al. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias[J]. Alzheimers Res Ther, 2021, 13(1):38.

Ozben T, Ozben S. Neuro-inflammation and anti-inflammatory treatment options for Alzheimer's disease[J]. Clin Biochem, 2019, 72:87-89.

Kinney JW, Bemiller SM, Murtishaw AS, et al. Inflammation as a central mechanism in Alzheimer's disease[J]. Alzheimers Dement(NY), 2018, 4:575-590.

Heneka MT, Carson MJ, Khoury JE, et al. Neuroinflammation in Alzheimer's disease[J]. Lancet Neurol, 2015, 14(4):388-405.

Nordengen K, Kirsebom BE, Henjum K, et al. Glial activation and inflammation along the Alzheimer's disease continuum[J]. J Neuroinflammation, 2019, 16(1):46.

Verberk IMW, Hendriksen HMA, van Harten AC, et al. Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project[J]. Neurobiol Aging, 2020, 89:99-107.

de Rojas I, Romero J, Rodríguez-Gomez O, et al. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE healthy brain initiative(FACEHBI)[J]. Alzheimers Res Ther, 2018, 10(1):119.

Mattsson N, Zetterberg H, Janelidze S, et al. Plasma tau in Alzheimer disease[J]. Neurology, 2016, 87(17):1827-1835.

Müller S, Preische O, Göpfert JC, et al. Tau plasma levels in subjective cognitive decline: results from the DELCODE study[J]. Sci Rep, 2017, 7(1):9529.

Chen ZC, Mengel D, Keshavan A, et al. Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease[J]. Alzheimers Dement, 2019, 15(3):487-496.

Mengel D, Janelidze S, Glynn RJ, et al. Plasma NT1 tau is a specific and early marker of Alzheimer's disease[J]. Ann Neurol, 2020, 88(5):878-892.

van Wijk N, Slot RER, Duits FH, et al. Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia[J]. Alzheimers Dement(Amst), 2017, 8:139-146.

de Leeuw FA, van der Flier WM, Tijms BM, et al. Specific nutritional biomarker profiles in mild cognitive impairment and subjective cognitive decline are associated with clinical progression: the NUDAD project[J]. J Am Med Dir Assoc, 2020, 21(10):1513.e1-1513.e17.

Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment[J]. Annu Rev Nutr, 2016, 36:211-239.

Mullan K, Cardwell CR, McGuinness B, et al. Plasma antioxidant status in patients with Alzheimer's disease and cognitively intact elderly: a Meta-analysis of case-control studies[J]. J Alzheimers Dis, 2018, 62(1):305-317.

Zhang N, Zhang LL, Li Y, et al. Urine AD7c-NTP predicts amyloid deposition and symptom of agitation in patients with Alzheimer's disease and mild cognitive impairment[J]. J Alzheimers Dis, 2017, 60(1):87-95.

Ku BD, Kim H, Kim YK, et al. Comparison of urinary Alzheimerassociated neural thread protein(AD7c-NTP)levels between patients with amnestic and nonamnestic mild cognitive impairment[J]. Am J Alzheimers Dis Other Demen, 2020, 35:1533317519880369.

Jin H, Guan SC, Wang R, et al. The distribution of urinary Alzheimer-associated neuronal thread protein and its association with common chronic diseases in the general population[J]. J Alzheimers Dis, 2018, 65(2):433-442.

Li YX, Kang MM, Wang HX, et al. Urinary Alzheimer-associated neuronal thread protein is not elevated in patients with subjective cognitive decline and patients with depressive state[J]. J Alzheimers Dis, 2019, 71(4):1115-1123.

Li YX, Kang MM, Sheng C, et al. Relationship between urinary Alzheimer-associated neuronal thread protein and apolipoprotein Epsilon 4 allele in the cognitively normal population[J]. Neural Plast, 2020, 2020:9742138.

Cosentino S, Scarmeas N, Helzner E, et al. APOE Epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease[J]. Neurology, 2008, 70(19 Pt 2):1842-1849.

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research advances of ferroptosis in Alzheimer's disease

Diagnosis of Alzheimer's disease based on whole-brain radiomics

Research progress of the characteristics of abnormal visual pathway and its clinical application in patients with Alzheimer's disease

Advances in the study of hippocampal subregion in Alzheimer's disease

Study on the relationship between¹¹C-PIB-PET/CT and neuropsychological scales in mild cognitive impairment and Alzheimer's disease

Related Author

Xu Pengjuan

Gao Jing

Qiao Xinrui

Zhao Jingwen

Yu Zhichao

Li Tao

Song Rao

Guo Dajing

Related Institution

Office of Academic Research,Tianjin Sino-German University of Applied Sciences

School of Integrative Medicine,Tianjin University of Traditional Chinese Medicine

Institute of Precision Medicine, GE Healthcare

Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University

Department of Neurology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

⁰